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Abstract: Oral cancer is a potentially fatal disease with an increasing incidence and an unchanged 5-year mortality rate. Unfortunately, 
oral cancer is often still late diagnosed, which leads to an increase in the likelihood of functional impairment due to treatment and mortal-
ity rate. Definitive diagnosis of oral cancer must be confirmed by scalpel biopsy and histological assessment. However despite its bene-
fits, scalpel biopsy is invasive and it is burdened by a potential morbidity. Furthermore, previous studies have suggested a high degree of 
intraobserver and interobserver variability regarding the histological evaluation of malignancy. As a consequence, in recent years there 
has been a growing and persisting demand towards developing new non-invasive, practical diagnostic tools that might facilitate the early 
detection of oral cancer. The most investigated non-invasive adjunctive techniques are vital staining, autofluorescence, chemilumines-
cence, narrow band imaging, and exfoliative cytology. Aim of the review is to critically describe these adjunctive aids and, after consid-
ering the literature data, an expert opinion on the effectiveness and the possible use of each technique will be provided. 
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1. INTRODUCTION 
 Oral cancer is the sixth most common cancer worldwide with 
increasing incidence and mortality rate [1-3]. Its early detection is 
crucial to improve survival and reduce morbidity, disfigurement, 
loss of function, poor quality of life, duration of treatment and hos-
pital costs [4, 5]. Despite numerous technological advances over the 
last fifty years, the survival rate linked to Oral Squamous Cell Car-
cinoma (OSCC) did not undergo a marked improvement, and it 
amounts to approximately 50% at five years [6]. The poor progno-
sis is due to several factors, including the advanced stage of disease 
(Stage III or IV) at diagnosis. Despite the oral cavity is a readily 
accessible site for a visual examination and palpation and the nature 
of the neoplastic process which is considered as a multi-stage phe-
nomenon, often evolving from oral Potentially Malignant Disorders 
(PMDs), OSCCs are still late diagnosed [7]. The 5-year survival 
rate for patients with primary oral cancer is still one of the lowest 
between the most invasive cancers, with loco-regional recurrence as 
primary cause of death [8]. Consequently, an intensive follow-up 
regimen is set up to discover recurrences or a second primary can-
cer as early as possible. OSCC stage at the time of diagnosis influ-
ences also the therapeutic options available with significant risk of 
acute and chronic side effects above all related to surgical/non-
surgical cancer therapy, reducing patient quality of life and the 
likelihood of long term survival [9].  
 The problem of the diagnostic delay could be partly solved by 
using two different approaches: first, screening programs to identify 
asymptomatic patients with suspected “high risk” lesions and then, 
improving the ability to detect early cancer lesions and to identify 
the PMDs having an increased risk of malignant transformation. To 
address these issues, several practical guides have been published 
and specific diagnostic tools have been developed to identify dys-
plasia and cancer lesions in asymptomatic patients with an oral 
abnormality. 
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 The diagnostic process begins with a comprehensive medical 
history and a head and neck examination. Dentists are profession-
ally responsible for providing a comprehensive oral examination 
and follow-up for their patients: an early diagnosis of oral cancer 
could mean the difference between life and death. The Conven-
tional Oral Exam (COE) under white light is a non-invasive and 
simple procedure whose goal is to detect any nodule, swelling, 
mucosal alteration (ulcerations, textural or colour changes) and/or 
unexplained neck lymph nodal adenopathy. COE has been consid-
ered as a life-saving test [10], which seems to be associated with a 
reduction in mortality among high-risk patients, especially when 
performed by highly qualified staff [11]. However, there is evi-
dence that the COE alone may be of limited value as a method of 
screening for oral malignancies [12, 13]. On the contrary, a rela-
tively high rate of sensitivity and specificity for COE has been re-
ported [14]. Although the clinical examination has been increas-
ingly used in the past and it has been considered as the first step of 
the diagnostic process in order to define a provisional diagnosis, 
which may be confirmed by further investigations, COE is strongly 
dependent on the experience in oral medicine of the clinician who 
performs it. The classic presentation of a potentially malignant 
disorder or early cancer lesions as a red or white lesion, persistent 
ulcer, provides some difficulties in the differential diagnosis with 
other benign conditions. In the presence of these lesions, COE is 
unable to identify those at “high risk” of progression. Furthermore, 
recent studies suggest that dysplasia or micro-invasive carcinoma 
can occur in clinically normal-appearing mucosa [15]. The clinical 
examination is absolutely useful in the discovery of oral lesions, but 
it seems not be able to identify accurately the biologically relevant 
lesions susceptible to neoplastic transformation. Currently, the gold 
standard diagnostic test for OSCC is an oral biopsy with histopa-
thology. Unfortunately, available studies reported inter-observed 
and interobserver variability in the histologic diagnosis of dysplasia 
and SCC, with reported agreement rate of only 56 % [16]. Clinical 
features of the lesion, specimen characteristics, artefacts resulting 
from crushing, fulguration or incorrect fixation and freezing, expe-
rience of the pathologist may play a part in determining the diagno-
sis [17, 18]. The grade of malignancy and depth of invasion are also 
important prognostic factors, strongly influenced by the size and the 
depth of biopsy [19-21]. 
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 This finding suggests the need to reduce the variability in the 
diagnosis of oral malignant lesions. This goal can be achieved im-
plementing techniques to early detect malignant alterations in the 
oral cavity. 
 However, there is a wide range of available tools that could be 
used in order to identify early signs of cancer. With so many com-
mercial diagnostic aids and adjunctive techniques to choose from 
these days, it becomes hard for the dentist to determine if a diagnos-
tic tool will be appropriate and useful for oral cancer screening.  
 Aim of the present paper is to present available evidence, if 
present, regarding the adjunctive techniques that may facilitate the 
early detection of oral cancer, citing and discussing also systematic 
review and meta-analysis on this topic. The diagnostic adjunctive 
techniques evaluated in this review are vital staining, chemilumi-
nescence, direct autofluorescence, exfoliative cytology and narrow-
band imaging. 
2. VITAL STAINING  
 The vital staining is a technique that exploits the properties of 
certain dyes to highlight some tissues, cells or cellular organelles. 
Available studies reported that the examination of the oral mucosa 
can be performed by staining with rose Bengal, already widely used 
to diagnose various ocular surface disorders [22, 23], methylene 
blue, recently proposed for screening gastrointestinal or prostate 
tumours because it seems less toxic to the human [24, 25] and 
Lugol’s solution, used to detection esophageal, gastrointestinal and 
gynecological abnormalities [26-28]. However, the more common 
vital stain in oral medicine is the toluidine blue (TB), a vital aci-
dophilic metachromatic stain of the thiazine group that has been 
effectively used in nuclear staining because of its binding to DNA 
nucleic acid. For this reason, it has been widely used to facilitate 
early detection of malignant lesions and by the surgeons to demar-
cate intra-operatively the extension of the lesion [29]. In recent 
years, the diagnostic ability of the TB staining was evaluated in a 
large number of studies. Epstein et al. showed the increase of the 
sensitivity of clinical examination after the application of TB in the 
detection of malignant lesions in high-risk patients [30]. There are 
some evidences that TB appears to improve precancerous lesion 
visualization by showing high-risk areas (areas of high cell prolif-
eration), therefore guiding biopsy. In vivo, toluidine blue stains 
deoxyribonucleic acid and may be retained in intracellular spaces of 
dysplastic [31]. Furthermore, it can be found in dysplastic cells and 
malignant tissues at sites of loss of tumour suppressor genes, poten-
tially predicting a malignant transformation of premalignant lesion 
or representing a OSCC at diagnosis [32]. Some Authors suggest 
also that the staining intensity after TB application may provide 
important information related to the binding of the stain with the 
molecular changes, predicting the neoplastic risk, most importantly 
in case of second OSCC or recurrence [33]. In another study, the 
Authors investigated the molecular profile of PMDs positive and 
negative after TB staining, by evaluating the relationship between 
intensity of staining and chromosomal aberrations [34]. The loss of 
heterozygosis, which occurs more frequently in samples positive to 
TB, may indicate an increased risk of neoplastic progression [35]. 
Zhang et al. showed a progression risk four times higher in lesions 
with mild dysplasia or benign histopathology, when they were posi-
tive to TB [33]. 
 The analysis of the current scientific evidence suggests that the 
sensitivity is higher in cancer cases than in cases of dysplasia. 
Overall, the sensitivity of this technique for detection of oral cancer 
range from 0.78 to 1.00 and specificity from 0.31 to 1.00 [36]. Al-
though TB is highly sensitive and moderately specific for malignant 
lesions, it is far less sensitive to PMDs with false-negative rates of 
up to 58% reported for identifying mild to moderate dysplasia [37]. 
 False negatives occur in a minority of cases, especially in the 
most recent case series in which the product has undergone some 
improvements. Nevertheless, the binding of TB to the nucleic acid 
may occur also in the mucosal ulceration, granulation tissue and 
inflammatory lesions thereby contributing to the number of false 
positives. However, unlike in the malignant lesions, the coloration 
of these traumatic benign lesions does not persist for a long time 
and is often located on the periphery of ulceration. To reduce the 
number of inflammatory lesions that can cause false positives, it is 
highly recommended a further assessment of non-healing wound 
after 15 days at least. 
 There is evidence that the TB test is helpful in identifying oral 
cancers, confirmed by the positive clinical experience of clinicians 
that have used this approach for years. Nevertheless, there is insuf-
ficient evidence to recommend for or against the stand-alone use of 
TB to enhance the identification of potentially malignant lesions in 
the general population. [38]. However, considering the dramatic 
implications of undiagnosed OSCC, and being the application of 
toluidine blue staining fast, minimally invasive, inexpensive and 
well patient-accepted, in this review the Authors would support the 
use of TB as a diagnostic tools in the hands of clinicians adequately 
trained in the exact interpretation of its results (Fig. 1a-b). It is also 
strongly recommended not using it as a substitute for biopsy, but 
rather as a complementary aid during the diagnostic phase, guiding 
the choice of the biopsy correct site and in the follow-up phase in 
order to early detect any recurrence or secondary OSCC. 
3. CHEMILUMINESCENCE 
 The term “chemiluminescence” refers to the emission of light 
radiation in the visible range after the electrons, excited by a 
chemical exergonic reaction, returning from the excited to the 
ground state; the potential energy of electronic transitions within 
the atoms or molecules is thus released in the form of light photons. 
This technique is correctly based on the reflectance phenomenon 
that indicates the proportion of incident light that a given surface is 
able to reflect. This technique has been used for many years as a 
diagnostic aid in the examination of cervical mucosa for the detec-
tion of potentially or malignant lesions. 
 Dehydration with acetic acid highlights the altered nuclear-
cytoplasmic ratio of the neoplastic epithelial cells and thus malig-
nant tissues assume a characteristic “aceto-white” appearance [39-
41]. This phenomenon can be further amplified by replacing con-
ventional lighting with diffuse blue-white chemiluminescent illu-
mination.  
 Considering the morphological similarities between cervical 
and oral epithelia, recently this technique has been proposed also 
for the oral cavity [42]. Approved by the FDA and introduced into 
the market under the name of ViziLite Plus
®
 (Zila Pharmaceuticals, 
Fort Collins, USA), Microlux DL
®
 (AdDent, Danbury, USA) and 
Orascoptic DK
™
 (Orascoptic, Middleton, USA), these diagnostic 
aids aim to enable a better identification, assessment and monitor-
ing of oral mucosal abnormalities in populations at increased risk of 
oral cancer. The main difference between the available disposals is 
that ViziLite Plus involves the use of single-use chemiluminescent 
stick, while Microlux DL and Orascoptic DX provide a blue-white 
LED fiber optic light.  
 ViziLite Plus
®
 consists of the emission of light from a chemical 
reaction between hydrogen peroxide and acetylsalicylic acid inside 
a capsule stick. During the chemical reaction, is produced a light 
white-blue with a wavelength between 430 nm and 580 nm that 
lasts for around 10 min. The first step of the procedure includes a 
first intra-oral examination under conventional white light in order 
to evaluate the location, extent, margins, presence of satellite le-
sions and visibility. Then, the intraoral exploration is repeated by 
using ViziLite light, after a 60-sec 1% acid acetic rinse in order to 
remove the glycoprotein barrier and slightly dry the oral mucosa. 
Under chemiluminescent light, the healthy tissue, able to absorb it, 
appears dark blue, while the abnormal tissue, characterized by ex-
cessive keratinization, increase in the ratio nucleus/cytoplasm, and 
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chronic inflammatory infiltrate, reflect the reflect the light and ap-
pears white (aceto-white lesion) with distinct margins [43, 44]. 
 Many studies have examined the reflectance of the tissue after 
rinsing with acetic acid as an aid to screening for oral cancer [36]. 
Although ViziLite is widely used in the United States for the 
evaluation of suspicious oral lesions, especially when used in asso-
ciation with the Toluidine Blue solution to mark the lesions to pos-
terior biopsy, evidence is lacking in support of its effectiveness. A 
recent review [45] reported that sensitivity of this device was 100% 
and specificity ranged from 0%-14.2%, showing that this method is 
not able to discern between benign hyperkeratosis, inflammatory 
diseases, OSCC and PMDs [46-49]. Moreover, the reported high 
sensitivity could be related to the design of the studies, which often 
involved only patients with mucosal lesions previously visualized 
under conventional light. In short, the evidence supporting the use 
of the system to aid the early detection of OSCC and PMDs is actu-
ally quite scarce.  
 However, available evidence suggests the use of chemilumines-
cence to enhance visual parameters of the lesions in terms of 
brightness, sharpness (margin delineation), surface texture and, in 
some cases, size of lesion compared with parameters after conven-
tional light. Due to the improved visual parameters, chemilumines-
cence-based device can be considered a useful tool for investigating 
oral mucosa and improving the visualization of white lesions [50], 
but does not increase the early detection of PMDs and is not recog-
nized an additional clinical benefit, since the additional costs that 
arise from its use [51, 52]. 
 The above-mentioned Microlux/DL
®
, which shares the basic 
principles of ViziLite, consists of a light-emitting diode (Power 
LED), a reusable light source that produces a diffused light. A re-
cent study evaluated the sensitivity and specificity of Microlux/DL, 
showing values of 77.8% and 70.7% respectively, although it is a 
poor discriminator for inflammatory, traumatic, and malignant le-
sions.
 Available studies reported that this approach does not seem to 
be significantly more useful than a clinical examination under con-
ventional LED white-light [53] (Fig. 2a-b).  
 Further controlled trials are needed to determine specifically the 
ability of these devices in early detecting PMDs clinically not visi-
ble under conventional light.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2a-b). a) Non homogenous leukoplakia on right lingual margin after 
clinical examination under conventional incandescent light; b) appearance 
of the lesion after clinical exam under chemiluminescent light. The tech-
nique did not result in any improvement of the lesion visualization. 
4. DIRECT AUTOFLUORESCENCE IMAGING 
 The direct autofluorescence is a method that exploits the ability 
of some molecules (fluorophores) to absorb a light of a particular 
wavelength and release it with a greater wavelength after short 
time. Normal healthy cells contain endogenous fluorophores such 
as Nicotinamide Adenine Dinucleotide (NADH), Flavin Adenine 
 
 
 
 
 
 
 
 
 
Fig. (1a-b). a) Oral leukoplakia on the right margin of the tongue is showed (black arrows). Note the presence of an erythro-leucoplakia lesion on the posterior 
third of the lingual border (black circle). b) It shows the same lesion after TB staining. The vital dye is strongly picked up by the posterior lesion (white circle) 
and does not stain the anterior lesion, where it is most evident the presence of red areas within the white lesion, thanks to the increase of contrast (white ar-
rows). After TB staining, a biopsy has been performed at both sites. The posterior lesion revealed to be histologically an erythroplakia with severe dysplasia, 
while the anterior lesion, no TB positive, was found to be a leukoplakia in the absence of dysplasia. (The color version of the figure is available in the elec-
tronic copy of the article). 
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Dinucleotide (FAD) and the cross-linked collagen, which show 
broad excitation spectra (250-450 nm) and release 500 nm light 
when subjected to a blue-violet light (400-460 nm), appearing as a 
green-apple areas. It has been demonstrated that changes in the 
structure and metabolism of the mucosae alter the distribution of 
fluorophores within the tissue [36]. 
  Abnormal cells have been shown not able to reflect fluorescent 
light, and thus absorb it, appearing as dark areas under 400-460 nm 
light.  
 Recent studies have shown that the autofluorescence imaging 
represents an incredibly promising tool in screening and diagnosis 
of premalignant conditions of the lung, cervix, skin, and finally the 
mouth [54-57]. The mechanism behind tissue autofluorescence 
tissue has been extensively described elsewhere [58, 59]. Briefly, 
loss of autofluorescence is believed to reflect the complex and pro-
gressive morphological and biochemical changes, typical of 
squamous epithelial carcinogenesis [60]. During cancer progres-
sion, the optical properties of epithelial surface and underlying 
stroma are altered, due to changes in structure (e.g. hyperkeratosis, 
hyperchromatin and increased cellular⁄nuclear pleomorphism) and 
metabolism (concentration of FAD and NADH within the epithe-
lium, as well as changes of the sub-epithelial stroma in terms of 
composition of the collagen matrix and elastin) [61]. These changes 
can alter the distribution of tissue fluorophores and as a conse-
quence, an increased light absorption or diffusion after stimulation 
with a blue (400–460 nm) light can be observed, which in turn re-
duces and modifies the detectable autofluorescence.  
 Several studies have evaluated the possibility of using tissue 
autofluorescence to differentiate and early detect cancers of the oral 
cavity [62, 63]. Commercially available diagnostic tools based on 
direct autofluorescence imaging are VELscope
®
 (LED Dental, 
Vancouver, British Columbia, Canada) and Sapphire
® 
Plus (Den-
Mat Holdings, Santa Maria, CA). These tools consist of portable 
devices developed in order to improve the detection capability of 
OSCC and PMDs [64, 65], by highlighting the loss of tissue fluo-
rescence correlated with some oral diseases, thanks the use of a 
400-460 nm light with a wavelength compatible with the emission 
spectrum of the endogenous fluorophores [66]. 
 This technique involves first a clinical examination under con-
ventional white light and, after turning off the lights, a further clini-
cal examination by using the handpiece device, keeping at a dis-
tance of about 5 cm from the oral cavity to optimize the visualiza-
tion of tissue fluorescence.  
 In the healthy oral cavity, there are components that may posi-
tively or negatively affect the tissue fluorescence. Some compo-
nents such as the blood hemoglobin and melanin have been shown 
able to reduce fluorescence, while fibrin, keratin and porphyrin 
appear to increase the fluorescence.  
 For this reason, a pattern of fluorescence within the oral mucosa 
can be normally described, depending on the oral site. For example, 
the fungiform papillae on the tongue dorsal surface appear as dark 
areas, since the end of filiform papillae are keratinized and emits a 
fluorescent light; along the tongue ventral surface, blood vessels 
appear dark, because of the high blood flow and finally the attached 
gingiva is often clear for its ultrastructural characteristics, being 
rich in keratin. 
 In addition, the oral cavity is naturally exposed to various de-
grees of mild inflammation and chronic irritation, and thus some 
oral sites could show a darker appearance characterized by poorly 
defined boundaries, caused by the increased inflow of blood. 
 If a dark area appear during direct fluorescence visualization, 
the oral lesion must be considered as a suspected one and the clini-
cal examination should be repeated by applying a pressure with the 
back of a dental mirror or a similar tool with a sweeping motion, in 
order to remove blood from the examined area. If the normal apple-
green fluorescence returns after this pressure, the lesion is likely to 
have an inflammatory component (Fig. 3a-b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3a-b). a) The figure shows a white lesion on the lingual right margin. 
In addition, it shows the presence of dark areas near to the white lesion; b) 
considering the lesion location and its clinical features being compatible 
with lingual varices, the compression of the dark area with subsequent reap-
pearance of tissue fluorescence has been performed. 
 
 Available evidence suggests that this technique can facilitate 
the detection of neoplastic lesions, with value of sensitivity and 
specificity ranging from 18.4% to 98% and from 81% to 100%, 
respectively [67-70]. Some Authors reported that autofluorescence-
based device can identify lesions which were not clinically evident 
[71, 72], as well as high risk areas for malignant transformation 
[71]. Limitations of autofluorescence imaging in discriminating 
between dysplastic and non-dysplastic have been reported in a re-
cent study [73], although another study showed that the device 
achieves a sensitivity of 98% and specificity of 100% when dis-
criminating normal mucosa from severe dysplasia/carcinoma in situ 
(CIS) or invasive carcinoma [66].  
 However, there is no full agree in literature regarding the ability 
of a autofluorescence-based device to distinguish between OSCC 
and other oral diseases such as aphthous ulcers, lichen planus and 
pemphigoid [74]. In a recent study, Poh et al. demonstrated that the 
direct tissue fluorescence visualization can enhance the delineation 
of the neoplastic margins [75]. In some cases, the loss of fluores-
cence was extended beyond 25 mm from the clinically visible (un-
der WL) margins of the lesion. This is extremely interesting, con-
sidering that one of the most difficult and contentious issues, about 
the treatment of OSCC, involves the decision concerning the 
amount of the surrounding normal-looking tissues that have to be 
removed in addition to the tumour mass. Generally, surgeons arbi-
trarily extend 10 mm or more beyond the margins of a neoplastic 
lesion, in order to remove any clinically occult high-risk areas [76]. 
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Unfortunately, this approach often fails because neoplastic or dys-
plastic areas often can be detected in surgical margins [77]. There-
fore, the feasible use of tissue fluorescence as a guide for the detec-
tion of field alterations and the extension of tumour margins during 
surgical excision is extremely interesting, but still a number of ef-
forts should be performed to validate this hypothesis. 
 There is also evidence of significant clinical value of this device 
in a referral clinic specialized in diagnosing and treating oral cancer 
[78]. This non-invasive tool should be seen as complementary de-
vice that cannot fully replace the histopathological assessment dur-
ing diagnosis and monitoring steps (Fig. 4a-c). During the diagnos-
tic moment, such device could enhance the visualization of clinical 
features of lesions and in particular, it could help clinicians in se-
lecting the correct site or sites to be submitted to biopsy, thanks to 
highlighting the margins. During the follow-up step, this tool could 
be useful, especially within an oral medicine secondary care facil-
ity, in clinical monitoring of OPMDs with definite histological 
diagnosis and in patients with a previous history of OSCC [79, 80]. 
5. EXFOLIATIVE CYTOLOGY 
 Exfoliative cytology consists in collecting cell samples from 
mucosal surfaces by means of scraping, brushing or rinse in order 
to detect any cytological alteration. This technique was first de-
signed for cervical cancer early detection [19] and it has recently 
proposed in oral medicine to detect primitive cell changes related to 
malignancy. This technique is also useful for the diagnosis of oral 
lesions related to viral and fungal diseases [81]. However, the main 
limitation of this method is the collection of disaggregated cells, 
which therefore does not allow the pathologist to reach a definitive 
diagnosis. Available studies reported that sensitivity and specificity 
of conventional exfoliative cytology in detecting OSCC lesions, 
ranged between 76.8%–100%, and 88.9%– 100%, respectively 
[82]. Brushing proved to be a more convenient collecting method 
compared with the wooden spatula when dealing with oral lesions 
[83]. The combined use of TB staining and brush cytology was 
found to be highly sensitive and moderately specific for OSCC 
lesions (6% false-negative rate) but less sensitive to the PMD le-
sions with a sensitivity of 89% and a specificity of 92% [37]. 
 Liquid-Based Cytology (LBC) is a sample filtration method 
originally developed to provide a near-monolayer of superficial 
cervical cells, which can be more easily inspected. A study reported 
that the application of LBC on oral cell samples collected by brush-
ing can significant improve cell distribution and smear thickness, 
leading to an easier identification of abnormal cells and reporting 
an higher sensitivity and specificity (95.1% and 99.0 % respec-
tively) [84]. However, the LBC method was designed just for su-
perficial cytology samples, thus it leads to the destruction of epithe-
lial fragments, so it is likely that the use of LBC for diagnosing oral 
lesions is of minimal value [51]. 
 Recently, a new technique has been developed to improve the 
reliability of this method in investigating mucosal lesions not sub-
jected to biopsy. OralCDx
® 
(OralScan Laboratories, Inc., Suffern, 
NY) is a computer-assisted method for the analysis of cellular sam-
ples collected by using a patented brush. This technique method, 
unlike the conventional cytology, allows obtaining a complete tran-
sepithelial sample in which all epithelial layers (superficial, inter-
mediate and basal) are represented. The full-thickness epithelium 
sampling is essential for a correct diagnosis [85]. 
 The sampling is obtained from a brush specifically designed to 
improve the inadequate samples of standard cytology, which re-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4a-c). a) Red lesion on the right maxillary tuber is highlighted; the lesion is barely visible under conventional incandescent light; b) after TB staining, the 
lesion shows a punctuating uptake of the vital dye; c) the visualization of the lesion under fluorescent light shows an area of loss of fluorescence with a greater 
surface than the same lesion under conventional light. Two biopsies (white circle) have been performed, after using the fluorescent light, in order to better 
visualize lesions margins; the histopathological analysis showed the presence of squamous cell carcinoma infiltrating massively the surgical margins. (The 
color version of the figure is available in the electronic copy of the article). 
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moves only the cells of the superficial epithelial layers. The device 
is repeatedly brushed over the entire lesion by using moderate pres-
sure in the same direction until the bleeding occurs, since it indi-
cates that the lamina propria was reached and the sample is consti-
tuted by the whole epithelium. The obtained sample is then released 
in the middle third of a glass, fixed with a 100% ethanol solution, in 
order to allow both hematoxylin-eosin and Papanicolaou staining. 
This technique could be useful in patients with multiple lesions 
within the oral cavity: it is unlikely to obtain a representative biopsy 
specimen from multiple oral lesions in a patient without a previous 
history of OSCC. Similarly, this technique can be used in patients 
with lack of compliance or reluctant to undergo a further biopsy 
again during the follow-up of previously diagnosed lesions. It is 
well established that the identification of aneuploidy is perhaps the 
best predictive marker of possible neoplastic transformation [86]. 
 It has been observed that the combination of cytological diag-
nosis and DNA-image cytometry may improve the overall sensitiv-
ity of the technique up to 100 %; this result may increase the appli-
cation of this tool in early diagnosis of dysplasia [87, 88]. The main 
markers used in the cytological analysis are p53, Ki-67, DNA 
ploidy status, epigenetic changes (hypermethylation of the promoter 
region), and genomic instability, such as loss of heterozygosity 
(LOH) e microsatellite instability [89-92]. 
 OralCDx
®
 has been shown to have a sensitivity and specificity 
over 90% [93] and it has been proposed as an useful screening tool, 
in specific clinical situations, in case of clinically suspicious le-
sions, since it is considered as a simple, relatively inexpensive, 
highly sensitive and specific method [93-95]. 
 The cytology is not comparable to the histological diagnosis 
and these two techniques should not be considered antithetical, but 
complementary: in case of abnormal cytology, it is strongly rec-
ommended that patient undergo a conventional biopsy [96].  
6. NARROWBAND IMAGING  
 The NarrowBand Imaging- NBI (Olympus Optical Co. Ltd, 
Tokyo, Japan) is a novel endoscopic technique based on the use of 
special optical filters that narrow the light bandwidth to enhance the 
visualization of the mucosa surface and microvasculature [97, 98]. 
NBI is a method to visualize the structure of the surface capillaries, 
in particular the intrapapillary capillary loops, and the vascular 
architecture of the submucosa, allowing the physician to have addi-
tional information to early identify atypical tissues. In neoplastic 
lesions, blood vessels are modified by dilation, meandering and 
calibre irregularities distinguishable from healthy oral mucosa [99]. 
Their morphological changes are useful for early diagnosing can-
cers, determining the depth of invasion and the margin of resection 
[100].  
 The NBI system was first used by Gono et al, [101] and today 
is widely used for the examination of the esophageal and pharyn-
geal mucosa [102]. Since oral mucosa and esophagus are both cov-
ered by squamous epithelium presenting similar vascular architec-
ture, it is likely that it could be powerful in detecting OSCC. In 
scientific literature only few case series have been reported in 
which the NBI system was used for early detection of precancerous 
lesions of the head and neck region, including pharynx and floor of 
the mouth [103]. Authors reported that the identification of the 
resection margin of the lesions thanks to NBI device was signifi-
Table 1. The main non-invasive aids developed for oral cancer screening: indications and literature evidence; adapted from "Evi-
dence-based clinical recommendations regarding screening for oral squamous cell carcinomas"- by Rethman M.P.-2010 
[64] 
 Indication Evidence 
Toluidine Blue 
May assist dental care providers, who 
have advanced training in the clinical 
assessment of potentially malignant disor-
ders and in the selection of the optimal 
biopsy site. 
Insufficient evidence to recommend for or against the stand-alone use 
of toluidine blue to enhance the identification of potentially malignant 
lesions in the general population.  
VELscope
®
 
(LED Dental, Vancouver, British 
Columbia, Canada) 
Could help identify potentially malignant 
lesions that may not be visible to the 
naked eye. 
There is some evidence that VELscope may improve the determina-
tion of surgical margins and selection of the optimal biopsy site; there 
is insufficient evidence that these devices improve patient compliance 
and that devices based on autofluorescence improve the detection of 
potentially malignant lesions 
ViziLite 
®
 
(Zila Pharmaceuticals, Fort Col-
lins, USA) 
MicroLux
®
 
(AdDent, Danbury, USA) 
Could enhance visual parameters of the 
lesions in brightness, sharpness, surface 
texture and size of lesion. 
There is insufficient evidence that devices based on tissue reflectance 
improve the detection of potentially malignant lesions. 
OralCDx
® 
(OralScan Laboratories, Inc., Suf-
fern, NY) 
May help the practitioner identify the 
presence of atypical cells in mucosal 
lesions. 
There is insufficient evidence to assess the validity of transepithelial 
cytology of seemingly innocuous mucosal lesions.  
There is evidence to use transepithelial cytology in case of suspicious 
multiple mucosal lesions, in case of noncompliant patients during 
their follow- up. 
Narrowband imaging (Olympus 
Optical Co. Ltd, Tokyo, Japan) 
May help the practitioner to enhance the 
visualization of the mucosa surface and 
microvasculature. 
There is no published evidence regarding the utility of narrowband 
imaging in oral cancer detection. 
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cantly improved when compared with other conventional systems, 
suggesting that this device may play an important role in the man-
agement of OSCC of the oral cavity [104]. NBI has several advan-
tages as a diagnostic tool. The equipment is easy to manage. It is 
non-invasive and stress-free for the patient. It can be used for post-
operative monitoring, for the PMDs follow-up and for establishing 
the lesion margin of resection. A recent study recommend a routine 
follow-up with NBI in patients with OSCC after treatment [105]. 
Since evidence is lacking, no firm conclusion can be drawn regard-
ing the usefulness of NBI in early detection of oral cancer, but fur-
ther studies are needed.
CONCLUSIONS 
 Early diagnosis of oral cancer is essential to ensure a better 
prognosis for patients in terms of disease-related morbidity and 
mortality. Screening by means of conventional clinical exam by 
using the incandescent light has been confirmed useful in detecting 
early and advanced oral cancer. However, the clinical features of 
the lesions alone cannot really allow distinguishing between benign 
and malignant lesions or selecting the potentially malignant lesions, 
which have a higher transformation risk. Up to now, oral biopsy is 
the only method to provide a definitive diagnosis in presence of oral 
suspicious lesions. Despite some limitations associated with the 
sampling site and the difficulty of classifying dysplasia, oral biopsy 
still represents the gold standard for OSCC and PMDs diagnosis. 
Furthermore, in presence of potentially malignant disorders, biopsy 
may allow distinguishing lesions at higher risk of transformation, 
but currently markers useful to detect oral lesions with inevitable 
risk of transformation are still lacking. 
 In a recent clinical trial conducted in India, where the preva-
lence of OSCC is very high, the Authors concluded that the conven-
tional clinical exam couldn’t lower the rate of disease-specific mor-
tality in the general adult population. Considering this aspect, the 
Authors conclude that any procedure that facilitates visualization of 
suspicious lesions could help the clinician in its detection [106]. 
 After reviewing the latest literature on the non-invasive meth-
ods for OSCC and PMDs diagnosis, there is insufficient evidence to 
recommend for or against the stand-alone use of these methods for 
identifying potentially malignant lesions.  
 Despite the lack of strong evidence that toluidine blue is a cost-
effective method of screening in the general population, toluidine 
blue can be used by clinicians experienced in oral medicine, thanks 
to its non-invasive nature and its capability to provide information 
regarding lesion margins and to guide the choice of biopsy site. 
 In the other reported studies, there is no evidence that devices 
based on tissue reflectance and autofluorescence can improve the 
detection of potentially malignant lesions. Some Authors have high-
lighted the possibility of early recognition of clinically occult le-
sions thanks to the direct visualization of tissue autofluorescence. 
However, these studies are only case series and therefore have a 
low level of evidence. The technique based on tissue autofluores-
cence provides an improvement in the visualization of some lesion 
clinical features, such as the margin extensions, and therefore, it 
should be considered as a complementary exam for the margin 
determination and selection of the optimal biopsy site in large or 
multifocal lesions or during surgery, by using oral biopsy as the 
“gold standard”. 
 In a recent paper, tissue autofluorescence method reported rela-
tively low values of sensitivity, indicating the probability of giving 
false negatives [107]. This is a great limitation in using this tech-
nique as screening tool in “high risk” population, since it can not 
always identify lesions with dysplasia, especially in case of mild 
dysplasia, which could represents the first histological change dur-
ing oral carcinogenesis. However, specificity values are high, sug-
gesting that the probability to give false positives is low. 
 Evidence in the literature to recommend the chemiluminescence 
method for early detection of oral cancer and potentially malignant 
disorders is strongly limited. Based on the collected data, the tech-
nique could be used just as an additional tool to improve clinical 
visualization, but only in case of white oral lesions. Moreover, al-
though it has been reported that these light-based methods can pro-
vide an aid in the detection of malignant lesions, the limitation of 
conventional clinical examination in discerning the low-risk lesions 
from those at high risk of transformation is not completely resolved. 
 Brush cytology, and in particular OralCDx
®
, has demonstrated 
validity as a method for identifying atypical cells disaggregated but, 
nevertheless, it must be emphasized that atypical findings can fre-
quently be obtained if the test is performed on reactive or inflam-
matory lesions. If the brush test is performed on oral lesions that 
may mimic clinically potentially malignant disorders, without con-
sidering the patient's history and the clinical history of the lesion, it 
can lead to false positives. This method should not be considered an 
alternative exam to biopsy, rather there are some recommendations 
about the usefulness of the technique in some specific clinical situa-
tions. These may include patients that have multiple oral lesions 
without a history of oral cancer, or patients with poor compliance, 
which poorly accept the possibility of being subjected to several 
biopsies during the follow-up. 
 In conclusion, we should explain that “insufficient evidence” 
does not necessarily mean that the technique is effective or not is, 
but instead means that the literature review did not find sufficient 
evidence to support a recommendation of using these methods. 
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